AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Overview
Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026?
AbbVie is a diversified pharmaceutical company that provides stable cash flows through its established drug portfolio. CRISPR Therapeutics AG is a clinical-stage biotechnology firm focused on the high-reward potential of gene therapy. These companies represent two ends of the healthcare spectrum, making them a fascinating pair for investors to compare.
Details
Many investors view the choice between these two as a classic biotech vs pharma comparison, where established stability meets high-stakes innovation. AbbVie focuses on discovering and commercializing medicines for complex health issues, with a strong emphasis on its immunology and aesthetics segments. The company distributes its products primarily through large wholesalers, including McKesson (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). Customer concentration like this adds a layer of risk to the business, as these three distributors handle nearly all of its pharmaceutical products in the United States.
Source
Originally published at www.fool.com.
Related Articles
- Josh Brown says investors are (re)learning how profitable these financial stocks are, including one on his list
- There Is Now An 83% to 90% Chance the Fed Raises Interest Rates on Sept. 16. Here's What History Says Would Happen to the S&P 500 Index Next.
- Anthropic Just Asked the AI Industry to Slow Down. Nothing in It Asks Anyone to Buy Fewer Nvidia Chips.